New developments in the management of Waldenström macroglobulinemia
Open Access
- 1 March 2017
- journal article
- review article
- Published by Taylor & Francis Ltd in Cancer Management and Research
- Vol. ume 9, 73-83
- https://doi.org/10.2147/CMAR.S94059
Abstract
New developments in the management of Waldenström macroglobulinemia Jithma P Abeykoon,1 Uday Yanamandra,2 Prashant Kapoor1,3 1Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA; 2Department of Hematology and Stem Cell Transplant, Army Hospital (Research & Referral), Delhi, India; 3Division of Hematology, Mayo Clinic, Rochester, MN, USA Waldenström macroglobulinemia (WM) is a rare, immunoglobulin M -associated lymphoplasmacytic lymphoma. With the recent discoveries of CXCR warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) and MYD88 mutations, our understanding of the biology of WM has expanded substantially. While WM still remains incurable, the field is rapidly evolving, and a number of promising agents with significant activity in this malignancy are being evaluated currently. In this review, we discuss the new developments that have occurred in WM over the past 15 years, with a focus on the role of ibrutinib, an oral BrutonâKeywords
This publication has 85 references indexed in Scilit:
- Neutropenia after rituximab treatmentCurrent Opinion in Hematology, 2012
- Stem cell transplant for Waldenström macroglobulinemia: an underutilized techniqueBone Marrow Transplantation, 2011
- In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma CellsClinical Cancer Research, 2011
- Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) GuidelinesMayo Clinic Proceedings, 2010
- Prognosis and treatment of Waldenström’s macroglobulinemiaTransfusion and Apheresis Science, 2010
- Immunoglobulin G Fc Receptor FcγRIIIa 158 V/F Polymorphism Correlates With Rituximab-Induced Neutropenia After Autologous Transplantation in Patients With Non-Hodgkin's LymphomaJournal of Clinical Oncology, 2010
- Primary Therapy of Waldenström Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180Journal of Clinical Oncology, 2009
- Thalidomide and rituximab in Waldenstrom macroglobulinemiaBlood, 2008
- Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia patients: a population-based study in SwedenBlood, 2008
- Initial immunoglobulin M ‘flare’ after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemiaCancer, 2004